Pioglitazone intratympanic gel

Drug Profile

Pioglitazone intratympanic gel

Alternative Names: Pioglitazone hydrochloride thermogel - Strekin; STR 001; STR001 thermogel; STR001-IT; SUB03834MIG

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Strekin
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hearing loss

Most Recent Events

  • 15 Feb 2017 Pharmacodynamics data from preclinical trials in Hearing loss released by Strekin
  • 27 Apr 2016 Strekin has patent protection for Pioglitazone intratympanic gel
  • 27 Apr 2016 Phase-II clinical trials in Hearing loss (Prevention) in France (Intratympanic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top